Alimentary Pharmacology & Therapeutics

Review article: uncomplicated diverticular disease of the colon
pp. 1379-1391(13)
Authors: PETRUZZIELLO, L.; IACOPINI, F.; BULAJIC, M.; SHAH, S.; COSTAMAGNA, G.

Review article: oesophageal spasm – diagnosis and management
pp. 1393-1402(10)
Authors: TUTUIAN, R.; CASTELL, D. O.

Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial
pp. 1403-1413(11)
Authors: MINER, P. B.; WEDEL, M. K.; XIA, S.; BAKER, B. F.

A Phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis
pp. 1415-1425(11)
Authors: VAN DEVENTER, S. J. H.; WEDEL, M. K.; BAKER, B. F.; XIA, S.; CHUANG, E.; MINER, P. B.

Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis
pp. 1427-1434(8)
Authors: MINER, P. B.; GEARY, R. S.; MATSON, J.; CHUANG, E.; XIA, S.; BAKER, B. F.; WEDEL, M. K.

Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease
pp. 1435-1442(8)
Authors: CREED, T. J.; PROBERT, C. S. J.; NORMAN, M. N.; MOORGHEN, M.; SHEPHERD, N. A.; HEARING, S. D.; DAYAN, C. M.

Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study
pp. 1443-1453(11)
Authors: ZEZOS, P.; PAPAIOANNOU, G.; NIKOLAIDIS, N.; PATSIAOURA, K.; PAPAGEORGIOU, A.; VASSILIADIS, T.; GIOULEME, O.; EVGENIDIS, N.

Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease
pp. 1455-1461(7)
Authors: D'INCÀ, R.; ANNESE, V.; DI LEO, V.; LATIANO, A.; QUAINO, V.; ABAZIA, C.; VETTORATO, M. G.; STURNIOLO, G. C.

Oats in the treatment of childhood coeliac disease: a 2-year controlled trial and a long-term clinical follow-up study
pp. 1463-1472(10)
Authors: HOLM, K.; MÄKI, M.; VUOLTEENAHO, N.; MUSTALAHTI, K.; ASHORN, M.; RUUSKA, T.; KAUKINEN, K.

Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease
pp. 1473-1477(5)
Authors: GUNARATNAM, N. T.; JESSUP, T. P.; INADOMI, J.; LASCEWSKI, D. P.

Efficacy and safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, placebo-controlled study
pp. 1479-1488(10)
Authors: KIENZLE-HORN, S.; VIX, J.-M.; SCHUIJT, C.; PEIL, H.; JORDAN, C. C.; KAMM, M. A.

The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor
pp. 1489-1498(10)
Authors: GOLDSTEIN, J. L.; LOWRY, S. C.; LANZA, F. L.; SCHWARTZ, H. I.; DODGE, W. E.